Mesoblast finishes dosing in back pain trial
Phase 3 trial for chronic lower back pain treatment concludes enrollment. Results expected mid-year.
Mesoblast announced the completion of patient treatment in its phase 3 trial evaluating remestemcel-L for chronic lower back pain.
The trial, designed to assess the investigational allogeneic mesenchymal stem cell therapy, enrolled patients across multiple sites. Mesoblast stated that dosing activities have now concluded, with data readouts anticipated in the middle of the year.
The study targets patients with chronic lower back pain due to degenerative disc disease, a condition with limited treatment options. Remestemcel-L is being evaluated for its potential to reduce pain and improve function compared to placebo.
Analysts will closely monitor the upcoming results, which could influence Mesoblast’s regulatory pathway and commercial prospects. The company has not disclosed further details on trial design or enrollment figures.
Mesoblast, a regenerative medicine company, did not provide a timeline for regulatory submissions pending the data.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →